Sun Pharma gains 4% in 2 days after launching cough syrup Chericof 12

Shares of Sun Pharmaceuticals Industries were up nearly 2 per cent at Rs 792.85 on the BSE in Wednesday’s intra-day trade, gaining 4 per cent in the past two trading days, after the company launched a novel formulation in cough management, Chericof12 (Dextromethorphan Hydrobromide 30mg and Chlorpheniramine Maleate 4 mg) in India. The stock of the pharmaceutical company was trading close to its 52-week high level of Rs 804.40 touched on August 3, 2021.

Chericof 12, the first prescription cough syrup in India which gives relief for up to 12 hours, is manufactured using Polistirex technology for sustained release of the drug. Chericof 12 is approved for patients of age group six years and above, said in a press release on Wednesday.

Polistirex Technology involves the complexation of two drugs, Dextromethorphan Hydrobromide and Chlorpheniramine maleate with resins. The resin granules of both drugs are added in suspension to form Chericof 12. Complexation of drugs with polistirex not only provides sustained release but also masks the bitter taste making it more palatable, the company said.

ICICI Securities recommended a ‘buy’ rating on with a price target of Rs 898 per share in three months. The pharma space has seen healthy correction in the last couple of weeks while broader remained buoyant. “We believe the sector is set to resume its next round of upside move after a round of consolidation. Recently, saw a recovery from its major support of Rs 750-755 levels. We expect fresh longs to follow the recent accumulation in the stock,” analysts at the brokerage firm said in their Quant Pick.

The stock has relatively outperformed most pharma stocks post its quarterly results. Significant delivery-based buying was observed in the stock in the range of Rs 750-760 in the September series and we expect these levels to act as major support for the stock in coming weeks, they added.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Source link

Share Market Today